DK3821891T3 - Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension - Google Patents

Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension Download PDF

Info

Publication number
DK3821891T3
DK3821891T3 DK20211109.2T DK20211109T DK3821891T3 DK 3821891 T3 DK3821891 T3 DK 3821891T3 DK 20211109 T DK20211109 T DK 20211109T DK 3821891 T3 DK3821891 T3 DK 3821891T3
Authority
DK
Denmark
Prior art keywords
treatment
arterial hypertension
pulmonary arterial
pulmonary
hypertension
Prior art date
Application number
DK20211109.2T
Other languages
Danish (da)
English (en)
Inventor
Edda Spiekerkoetter
Marlene Rabinovitch
Philip A Beachy
David Solow-Cordero
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK3821891T3 publication Critical patent/DK3821891T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK20211109.2T 2011-05-02 2012-04-30 Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension DK3821891T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481317P 2011-05-02 2011-05-02
EP12779354.5A EP2704711B1 (en) 2011-05-02 2012-04-30 Use of fk506 for the treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
DK3821891T3 true DK3821891T3 (da) 2023-09-04

Family

ID=47108011

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20211109.2T DK3821891T3 (da) 2011-05-02 2012-04-30 Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension
DK12779354.5T DK2704711T3 (da) 2011-05-02 2012-04-30 Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12779354.5T DK2704711T3 (da) 2011-05-02 2012-04-30 Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension

Country Status (19)

Country Link
US (6) US9474745B2 (enExample)
EP (3) EP4279130A3 (enExample)
JP (1) JP6177765B2 (enExample)
AU (2) AU2012250974B9 (enExample)
CA (1) CA2834368C (enExample)
CY (1) CY1123900T1 (enExample)
DK (2) DK3821891T3 (enExample)
ES (2) ES2954905T3 (enExample)
FI (1) FI3821891T3 (enExample)
HR (1) HRP20210245T1 (enExample)
HU (1) HUE053229T2 (enExample)
LT (1) LT2704711T (enExample)
PL (1) PL2704711T3 (enExample)
PT (2) PT2704711T (enExample)
RS (1) RS61480B1 (enExample)
SI (1) SI2704711T1 (enExample)
SM (1) SMT202100085T1 (enExample)
WO (1) WO2012151153A1 (enExample)
ZA (1) ZA201307905B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016114993A1 (en) * 2015-01-13 2016-07-21 Selten Pharma, Inc. Combination therapy for pulmonary hypertension
EP3294294A4 (en) * 2015-05-08 2019-01-02 Vivus, Inc. Compositions and methods for the treatment or prevention of pulmonary hypertension
CN105062976B (zh) * 2015-08-05 2018-05-11 中国医学科学院基础医学研究所 肺动脉高压治疗药物的干细胞筛选模型及应用
ES2683921B1 (es) * 2017-03-28 2019-04-22 Univ Vigo Método para la determinación del pronóstico en sujetos diagnosticados con hipertensión arterial pulmonar
CA3064275A1 (en) * 2017-05-19 2018-11-22 The Board Of Trustees Of The Leland Stanford Junior University Enzastaurin and fragile histidine triad (fhit)-increasing agents for the treatment of pulmonary hypertension
US12440479B2 (en) 2018-03-28 2025-10-14 Georg-August-Universitaet Goettingen, Stiftung Oeffentlichen Rechts, Universitaetsmedizin Prevention or treatment of chronic organ injury

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
FR2936060B1 (fr) 2008-09-17 2010-11-19 Assist Publ Hopitaux De Paris Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire.
KR20110086803A (ko) * 2008-10-22 2011-08-01 샘 애머 앤드 컴퍼니, 인코오포레이티드 폐동맥 고혈압의 치료방법

Also Published As

Publication number Publication date
CA2834368A1 (en) 2012-11-08
US20170007585A1 (en) 2017-01-12
AU2012250974B2 (en) 2017-05-04
SI2704711T1 (sl) 2021-04-30
RS61480B1 (sr) 2021-03-31
WO2012151153A1 (en) 2012-11-08
PL2704711T3 (pl) 2021-07-05
DK2704711T3 (da) 2021-02-22
ES2856173T3 (es) 2021-09-27
HUE053229T2 (hu) 2021-06-28
JP2014513121A (ja) 2014-05-29
ZA201307905B (en) 2015-05-27
US20220184042A1 (en) 2022-06-16
EP2704711A1 (en) 2014-03-12
AU2012250974A1 (en) 2013-11-14
CY1123900T1 (el) 2022-05-27
AU2012250974B9 (en) 2017-05-18
EP2704711B1 (en) 2020-12-02
US20180185340A1 (en) 2018-07-05
PT3821891T (pt) 2023-08-31
US20140135358A1 (en) 2014-05-15
CA2834368C (en) 2020-02-18
EP3821891A1 (en) 2021-05-19
EP3821891B1 (en) 2023-06-07
HRP20210245T1 (hr) 2021-04-02
EP4279130A2 (en) 2023-11-22
FI3821891T3 (fi) 2023-08-24
AU2017210583A1 (en) 2017-08-24
US20230404982A1 (en) 2023-12-21
SMT202100085T1 (it) 2021-05-07
EP2704711A4 (en) 2014-11-19
AU2017210583B2 (en) 2019-02-07
US9474745B2 (en) 2016-10-25
ES2954905T3 (es) 2023-11-27
US20190091208A1 (en) 2019-03-28
JP6177765B2 (ja) 2017-08-09
EP4279130A3 (en) 2024-02-21
LT2704711T (lt) 2021-04-26
PT2704711T (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
LTC2552902I2 (lt) Nenukleozidinės reversinės transkriptazės inhibitoriai
DK3141224T3 (da) Stomipose med filterkonstruktion
IL231228A0 (en) Bicyclic heterocycle derivatives for the treatmen t of pulmonary arterial hypertension
DK2691443T3 (da) Konjugerede lipomerer og anvendelser af disse
EP2663266C0 (en) ENDOPROSTHESIS
PL2544682T3 (pl) Fitokannabinoidy w leczeniu glejaka
EP2539521A4 (en) FRAMEWORK
DK2785801T4 (da) Fremgangsmåde til formindskelse af isdannelse på et underlag
EP2774585A4 (en) Stent
DK2733304T3 (da) Indstrømningsanordning
DK3392252T3 (da) Pyrimido-pyridazinonforbindelser og deres anvendelse
DK2715352T3 (da) Fremgangsmåde til vurdering af risiko for pml
CO6870004A2 (es) Métodos de modulación de un microarn en el tratamiento de la hipertensión arterial pulmonar
DK3821891T3 (da) Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension
DK3311810T3 (da) Anvendelse af sulcardin til behandling af atrieflimmer
EP2750559A4 (en) WATER HEATER
IL229537A0 (en) Hypertension and hyperuricemia
NO20120892A1 (no) Truge med integrert ledd
EP3396052C0 (en) OPTIMIZED DISHWASHER AND ITS USE
DK2621517T4 (da) Sammensætning til anvendelse i behandlingen af infertilitet
EP2786716A4 (en) ATHERECTOMY DEVICE
EP2767208A4 (en) DISHWASHER
DK2429345T3 (da) Strandkurv
FI20105023A0 (fi) Tiivistetty suodatin
DK2782961T3 (da) Polypropylen med lav fluidretention